{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:45:49Z","timestamp":1788997549701,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40262-021-01082-2","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T06:02:45Z","timestamp":1636783365000},"page":"439-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis"],"prefix":"10.1007","volume":"61","author":[{"given":"Paul","family":"van den Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Mesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Snelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Seelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Heinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Garmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-3423","authenticated-orcid":false,"given":"Thomas","family":"Eissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"crossref","unstructured":"Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2020.","DOI":"10.1093\/ndt\/gfaa294"},{"issue":"5","key":"1082_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333\u201344.","journal-title":"Am J Nephrol"},{"issue":"23","key":"1082_CR3","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"key":"1082_CR4","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2020.","DOI":"10.1161\/CIRCULATIONAHA.121.055066"},{"issue":"1","key":"1082_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41581-020-00371-6","volume":"17","author":"SJ Allison","year":"2021","unstructured":"Allison SJ. Finerenone in chronic kidney disease. Nature Rev Nephrol. 2021;17(1):13.","journal-title":"Nature Rev Nephrol"},{"issue":"23","key":"1082_CR6","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMe2031382","volume":"383","author":"JR Ingelfinger","year":"2020","unstructured":"Ingelfinger JR, Rosen CJ. Finerenone: halting relative hyperaldosteronism in chronic kidney disease. N Engl J Med. 2020;383(23):2285\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"1082_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71(4):599\u2013608.","journal-title":"Hypertension"},{"key":"1082_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","volume":"168","author":"D Lavall","year":"2019","unstructured":"Lavall D, Jacobs N, Mahfoud F, Kolkhof P, Bohm M, Laufs U. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem Pharmacol. 2019;168:173\u201383.","journal-title":"Biochem Pharmacol"},{"key":"1082_CR9","doi-asserted-by":"crossref","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021.","DOI":"10.1056\/NEJMoa2110956"},{"issue":"11","key":"1082_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46(11):1546\u201355.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1082_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","volume":"43","author":"R Heinig","year":"2018","unstructured":"Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo. Eur J Drug Metab Pharmacokinet. 2018;43(6):715\u201327.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"1082_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","volume":"44","author":"R Heinig","year":"2019","unstructured":"Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with mild or moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2019;44(5):619\u201328.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"1082_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13318-020-00610-y","volume":"45","author":"R Heinig","year":"2020","unstructured":"Heinig R, Gerisch M, Bairlein M, Nagelschmitz J, Loewen S. Results from drug-drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications. Eur J Drug Metab Pharmacokinet. 2020;45(4):433\u201344.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"1082_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone: results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384.","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"1082_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488\u2013501.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"1082_CR16","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394.","journal-title":"JAMA"},{"issue":"3","key":"1082_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, et al. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1082_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31(4):758\u201365.","journal-title":"J Diabetes Complications"},{"key":"1082_CR19","doi-asserted-by":"publisher","unstructured":"Goulooze B, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, et al. Finerenone dose-exposure-serum potassium response analysis of FIDELIO-DKD phase 3: the role of dosing, titration, and inclusion criteria. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-021-01083-1(Accepted).","DOI":"10.1007\/s40262-021-01083-1"},{"issue":"Suppl5","key":"1082_CR20","first-page":"198","volume":"30","author":"A Grothey","year":"2019","unstructured":"Grothey A, Hoefman S, Ruppert M, Vis P, Zisowsky J, Fiala-Buskies S, et al. Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR). Ann Oncol. 2019;30(Suppl5):198\u2013252.","journal-title":"Ann Oncol"},{"issue":"2","key":"1082_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"4","key":"1082_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1082_CR23","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1007\/s00125-008-1086-9","volume":"51","author":"RA Chudleigh","year":"2008","unstructured":"Chudleigh RA, Ollerton RL, Dunseath G, Peter R, Harvey JN, Luzio S, et al. Performance of the revised \u201c175\u201d modification of diet in renal disease equation in patients with type 2 diabetes. Diabetologia. 2008;51(9):1714\u20138.","journal-title":"Diabetologia"},{"issue":"6","key":"1082_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1082_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","volume":"56","author":"M Horio","year":"2010","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD Epidemiology Collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56(1):32\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1082_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1082_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40262-014-0146-1","volume":"53","author":"L Lalande","year":"2014","unstructured":"Lalande L, Charpiat B, Leboucher G, Tod M. Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet. 2014;53(6):521\u201332.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1082_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.33594\/000000003","volume":"52","author":"BH Ali","year":"2019","unstructured":"Ali BH, Al Salam S, Al Suleimani Y, Al Za\u2019abi M, Abdelrahman AM, Ashique M, et al. Effects of the SGLT-2 inhibitor canagliflozin on adenine-induced chronic kidney disease in rats. Cell Physiol Biochem. 2019;52(1):27\u201339.","journal-title":"Cell Physiol Biochem"},{"issue":"12","key":"1082_CR29","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/pan.13272","volume":"27","author":"BJ Anderson","year":"2017","unstructured":"Anderson BJ, Holford NH. What is the best size predictor for dose in the obese child? Paediatr Anaesth. 2017;27(12):1176\u201384.","journal-title":"Paediatr Anaesth"},{"issue":"1","key":"1082_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MJT.0000000000000506","volume":"26","author":"N Mansoor","year":"2019","unstructured":"Mansoor N, Ahmad T, Alam Khan R, Sharib SM, Mahmood I. Prediction of clearance and dose of midazolam in preterm and term neonates: a comparative study between allometric scaling and physiologically based pharmacokinetic modeling. Am J Ther. 2019;26(1):32\u20137.","journal-title":"Am J Ther"},{"issue":"24","key":"1082_CR31","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"3","key":"1082_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282\u20137.","journal-title":"Kidney Int"},{"issue":"3","key":"1082_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2011.132","volume":"80","author":"MR Weir","year":"2011","unstructured":"Weir MR. Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? Kidney Int. 2011;80(3):235\u20137.","journal-title":"Kidney Int"},{"issue":"2","key":"1082_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ahj.2015.05.008","volume":"170","author":"EF Lewis","year":"2015","unstructured":"Lewis EF, Claggett B, Parfrey PS, Burdmann EA, McMurray JJ, Solomon SD, et al. Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. Am Heart J. 2015;170(2):322\u20139.","journal-title":"Am Heart J"},{"issue":"10","key":"1082_CR35","doi-asserted-by":"publisher","first-page":"e48407","DOI":"10.1371\/journal.pone.0048407","volume":"7","author":"L Lipworth","year":"2012","unstructured":"Lipworth L, Mumma MT, Cavanaugh KL, Edwards TL, Ikizler TA, Tarone RE, et al. Incidence and predictors of end stage renal disease among low-income blacks and whites. PLoS ONE. 2012;7(10):e48407.","journal-title":"PLoS ONE"},{"issue":"15","key":"1082_CR36","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01082-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:04:47Z","timestamp":1646283887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01082-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01082-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"8 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LAP&P conducted the analysis as contract research for Bayer. However, LAP&P (PB, MR, EM, NS) was not paid to contribute to manuscript preparation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PB, MR, EM, are NS are employed by LAP&P, a CRO working for Bayer. AS, RH, AJ, DG, JL, and TE are Bayer employees and potential shareholders of Bayer AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by international review boards, independent ethics committees, and competent authorities according to national and international regulations. FIDELIO-DKD was conducted in accordance with the ICH Harmonized Tripartite Guideline for Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided written informed consent before entering the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All study participants provided written informed consent before entering the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data will be made available in an electronic repository in future, at a date to be specified by Bayer.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The NONMEM analysis code is provided as ESM.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PB: wrote manuscript, designed research, performed popPK\/TTE analysis, analyzed data; MR: wrote manuscript, performed TTE analysis, analyzed data; EM: wrote manuscript, performed popPK, analyzed data; NS: wrote manuscript, designed research, supported popPK\/TTE analysis, analyzed data; AS: wrote manuscript, designed research, programmed and analyzed data; RH: wrote manuscript, designed research; AJ: wrote manuscript, designed research; DG: wrote manuscript, designed research; JL: wrote manuscript, designed research; TE: wrote manuscript, designed research, steered analysis, analyzed data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}